Healthy
Conditions
Keywords
STAR particles, Skin
Brief summary
The objective of this study is to find out the best method of applying STAR particles to the skin. STAR particles are very small particles with microneedles on the surface that can increase and create small punctures in the skin. The small punctures should allow for different topical medications to work more effectively. This is important to understand the potential use of STAR particles in future topical medications. This study will not use any medication with active ingredients. The study will include healthy adult participants. The first visit will be to collect medical information and assess eligibility in the study. The second visit will have the application of STAR particles on different areas of the arm, hand, and face with different pressures to determine what the most effective method of application is. The skin will be evaluated after the application, and surveys will be collected on the tolerability of the application.
Detailed description
The goal of this study is to identify the most efficacious pressure of administration and the minimum number of rubbing cycles necessary to perforate the stratum corneum (the outermost layer of the skin). Many medical conditions are treated through the topical application of a therapeutic compound formulated into a gel, cream, ointment, or lotion (e.g., eczema, psoriasis, actinic keratosis, cutaneous warts). This is especially true in dermatology, in which the skin is often the primary site of action. Topicals (i.e., drugs applied to the skin's surface) allow patients to easily self-apply these therapies without the need for painful or difficult-to-use medical technologies (e.g., hypodermic needles) or the risks associated with systemic exposure to a drug (e.g., oral, intravenous, or intramuscular administration). Despite the advantages associated with topical delivery, the skin serves as a barrier to the transport of most external compounds. There are several techniques to overcome the skin barrier. Several studies have been conducted to increase skin permeability using various methods, including chemical, biochemical, and physical approaches. However, chemical and biochemical methods do not appear to be broadly useful for the delivery of large molecule therapeutics (e.g., peptides, proteins, genetic material) across the skin. STAR particles are millimeter-scale particles with micron-scale projections made of biocompatible materials that painlessly disrupt the stratum corneum. As STAR particles are rubbed on the skin, their microscopic projections create micron-scale pores in the stratum corneum to increase skin permeability to topical compounds independent of physicochemical properties. After the arms of the STAR particle puncture the skin, the elastic forces of the skin push the particles out. The first 10 participants will receive the 8 interventions (different application pressures) plus the control (Site and treatment will not be randomly assigned to the arm) by the investigator. In addition, two applications of STAR particles will be applied to one of the hands. After these participants have completed the study, an interim analysis will be performed. At this point, a decision will be made by the investigator to determine if changes in STAR particle administration will be implemented for the next 10 participants.
Interventions
A 1.5-gram dose of STAR particles (10% concentration in aloe vera ointment) will be applied to the eight application sites (forearm and hand). Two rubbing cycles (30 and 60 cycles at a minimum of 1 cycle/second) and three pressures (40, 60, and 80 kPa) will be evaluated
A 100mg dose of the gel without STAR particles is applied to the control site (the forearm for all participants and, additionally, the face for participants 11-20).
Sponsors
Study design
Eligibility
Inclusion criteria
* Adult, 18 - 39 years of age * In good general health as determined by a medical history * Willing and able to provide informed consent and follow all study requirements * Not pregnant and does not desire to become pregnant in the subsequent two months
Exclusion criteria
* Has a known allergy or sensitivity to aloe vera or alumina * Has any skin disorders or skin allergies * Has any medical condition that may affect skin or skin sensation * Has abnormal (e.g., tattooed) skin at forearms * Has known neurological condition affecting sensory function or perception of pain * Has inflammatory bowel disease * Has applied skin ointment or cream to forearms in the previous 24 hours * Has a major congenital or chromosomal abnormality known to affect the skin * Has taken pain medication in the last 24 hours * Is currently participating in another interventional clinical trial * Has previously participated in a STAR particle interventional clinical trial * Is pregnant or wishing to be pregnant * Has any condition (social or medical), which in the opinion of the investigator would make study participation unsafe, would interfere with adherence to the clinical study requirements, or would complicate data interpretation
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Transepidermal Water Loss (TEWL) | Before application, 20 minutes after application, and 30 minutes after application | Trans-epidermal water loss (TEWL) measurement (only for the first 10 participants 1-10) before and after application of STAR particles \[(T0 (before), T20 (after), T30 (after)\]. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Sensation After Application of STAR Particles (Part 2 Only) | Immediately After STAR particles application | Measured using a Likert-type scale ranging from 0 to 5, where 0 = No Pain and 5 = Severe Pain. Higher scores indicate greater perceived sensation. Sensation was evaluated only among participants in the STAR Particles study, Part 2. |
| Evaluate Pain Using the Visual Analog Pain Scale (VAPS) After Application of the STAR Particles (Part 2 Only) | Immediately After STAR particles application | The Visual Analog Pain Scale is a tool used to measure a person's pain intensity. It is a unidimensional scale, typically represented by a straight line often depicted as a 100 mm line with one end marked "no pain" (0) and the other marked "worst imaginable pain" (100). For this outcome, results will be reported as a percentage of the 100 mm VAPS scale, where 0% corresponds to no pain and 100% corresponds to the worst imaginable pain. A higher percentage indicates greater pain intensity. VAPS was evaluated only among participants in the STAR Particles study, Part 2. |
| Number or Participants Who Reported Standard Adverse Event (AE) | Up to 5 days after the STAR particles removal (for a total of 5 days) | Number of participants during each period of participation who reported any adverse events after the removal of the STAR particles at any of the sites of application. |
Countries
United States
Contacts
Emory University
Participant flow
Recruitment details
Participants were recruited in Atlanta, Georgia, USA. Participant enrollment began February 7, 2024, and all follow-up was complete by December 7, 2024.
Pre-assignment details
This was an ADAPTIVE STUDY DESIGN so that after reviewing the data collected from the first 10 participants (Part 1), conditions were altered so that the ideal conditions (cycles and pressure application) discovered from Part 1 (first 10 participants) would be used for the next 10 participants (11 - 20) in Part 2 of the study. In Part 2, each subject had STARs applied to the right head/face and the right forearm, and a control was applied to the left head/face and the left forearm.
Baseline characteristics
| Characteristic | — |
|---|---|
| Age, Categorical <=18 years | 0 Participants |
| Age, Categorical >=65 years | 0 Participants |
| Age, Categorical Between 18 and 65 years | 20 Participants |
| Age, Continuous | 25.50 years STANDARD_DEVIATION 5.47 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 1 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 5 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 4 Participants |
| Race (NIH/OMB) Black or African American | 1 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 5 Participants |
| Race (NIH/OMB) White | 8 Participants |
| Region of Enrollment United States | 10 participants |
| Sex: Female, Male Female | 13 Participants |
| Sex: Female, Male Male | 2 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 10 | 0 / 10 |
| other Total, other adverse events | 0 / 10 | 0 / 10 |
| serious Total, serious adverse events | 0 / 10 | 0 / 10 |